title: Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.
abstract: BACKGROUND
  Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux. Response of laryngitis to treatment with acid-suppressive therapy supports this causal link.
  
  
  OBJECTIVE
  To determine the prevalence of gastro-oesophageal reflux disease in patients with chronic laryngitis and response to proton-pump inhibitor therapy.
  
  
  METHODS
  Patients with chronic laryngitis were recruited. The frequency and severity of reflux and laryngeal symptoms were scored and laryngitis graded by laryngoscopy. All patients underwent esophagogastroduodenoscopy and 24-h ambulatory pH monitoring before receiving lansoprazole 30 mg b.d. for 8 weeks.
  
  
  RESULTS
  The prevalence of gastro-oesophageal reflux disease was 65.6% (21 of 32). Based on positive pH test, the prevalence was 25% (eight of 32). The change in laryngeal symptom score and laryngitis grade was significantly higher in GERD compared with non-GERD patients (P = 0.010 for both). The proportion of patients with marked/moderate improvement in laryngeal symptoms were significantly higher in patients with reflux (14 of 21, 67%) compared to those without reflux (two of 11, 18%; P = 0.026).
  
  
  CONCLUSIONS
  The prevalence of gastro-oesophageal reflux disease amongst our patients with chronic laryngitis was high. The response to treatment with proton-pump inhibitors in patients with reflux disease compared to those without underlined the critical role of acid reflux in a subset of patients with chronic laryngitis.
authors.affiliation: Division of Gastroenterology, Facultu of Medicine, University of Malaysia, Kuala Lumpur, Malaysia.
authors.forename: C S
authors.initials: CS
authors.lastname: Qua
authors.forename: C H
authors.initials: CH
authors.lastname: Wong
authors.forename: K
authors.initials: K
authors.lastname: Gopala
authors.forename: K L
authors.initials: KL
authors.lastname: Goh
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications*; D006801:Humans; D064747:Lansoprazole; D007827:Laryngitis / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000627:therapeutic use
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D064747:Lansoprazole